Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Recall Authority, 71041-71042 [2011-29512]
Download as PDF
Federal Register / Vol. 76, No. 221 / Wednesday, November 16, 2011 / Notices
manufacturer has and maintains as a
normal course of its doing business.
Thus, the burden to the food
manufacturer is limited to assembling
and retaining the records, which FDA
estimates will take 1 hour annually.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
State Petitions for Exemption for
Preemption
Food and Drug Administration
[Docket No. FDA–2011–N–0402]
[FR Doc. 2011–29478 Filed 11–15–11; 8:45 am]
BILLING CODE 4160–01–P
AGENCY:
Food and Drug Administration,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘State Petitions for Exemption for
Preemption’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
3793.
SUPPLEMENTARY INFORMATION: On August
29, 2011, the Agency submitted a
proposed collection of information
entitled ‘‘State Petitions for Exemption
for Preemption’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0277. The
approval expires on October 31, 2014. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
SUMMARY:
Food and Drug Administration
[Docket No. FDA–2011–N–0425]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Infant Formula Recall Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Infant Formula Recall Regulations’’ has
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
3793.
On August
30, 2011, the Agency submitted a
proposed collection of information
entitled ‘‘Infant Formula Recall
Regulations’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0188. The
approval expires on October 31, 2014. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: November 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–29511 Filed 11–15–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0793]
Dated: November 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Device
Recall Authority
[FR Doc. 2011–29479 Filed 11–15–11; 8:45 am]
AGENCY:
BILLING CODE 4160–01–P
HHS.
VerDate Mar<15>2010
17:45 Nov 15, 2011
Jkt 226001
PO 00000
Food and Drug Administration,
Frm 00088
Fmt 4703
Sfmt 4703
ACTION:
71041
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection requirements
for medical device recall authority.
DATES: Submit either electronic or
written comments on the collection of
information by January 17, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
SUMMARY:
E:\FR\FM\16NON1.SGM
16NON1
71042
Federal Register / Vol. 76, No. 221 / Wednesday, November 16, 2011 / Notices
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Medical Device Recall Authority—21
CFR Part 810 (OMB Control Number
0910–0432)—Extension
This collection of information
implements section 518(e) of the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) (21 U.S.C. 360h(e)) and part
810 (21 CFR part 810), medical device
recall authority provisions. Section
518(e) of the FD&C Act provides FDA
with the authority to issue an order
• Notify health professionals and
device user facilities of the order, and
• Instruct those professionals and
facilities to cease use of the device;
2. FDA will provide the person named
in the cease distribution and
notification order with the opportunity
for an informal hearing on whether the
order should be modified, vacated, or
amended to require a mandatory recall
of the device; and
3. After providing the opportunity for
an informal hearing, FDA may issue a
mandatory recall order if the Agency
determines that such an order is
necessary.
The information collected under the
recall authority provisions will be used
by FDA to do the following: (1) Ensure
that all devices entering the market are
safe and effective, (2) accurately and
immediately detect serious problems
with medical devices, and (3) remove
dangerous and defective devices from
the market.
FDA estimates the burden of this
collection of information as follows:
requiring an appropriate person,
including manufacturers, importers,
distributors, and retailers of a device, if
FDA finds that there is reasonable
probability that the device intended for
human use would cause serious adverse
health consequences or death, to: (1)
Immediately cease distribution of such
device, (2) immediately notify health
professionals and device-user facilities
of the order, and (3) instruct such
professionals and facilities to cease use
of such device.
Further, the provisions under section
518(e) of the FD&C Act set out the
following three-step procedure for
issuance of a mandatory device recall
order:
1. If there is a reasonable probability
that a device intended for human use
would cause serious, adverse health
consequences or death, FDA may issue
a cease distribution and notification
order requiring the appropriate person
to immediately:
• Cease distribution of the device,
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 CFR Section
No. of responses
per respondent
Total annual
responses
Average burden
per response
Total hours
810.10(d) ..........................................................
810.11(a) ..........................................................
810.12(a) and (b) .............................................
810.14 ..............................................................
810.15(a), (b), and (c) ......................................
810.15(d) ..........................................................
810.15(e) ..........................................................
810.16(a) and (b) .............................................
810.17(a) ..........................................................
2
1
1
2
2
2
10
2
2
1
1
1
1
1
1
1
12
1
2
1
1
2
2
2
10
24
2
8
8
8
16
12
4
1
40
8
16
8
8
32
24
8
10
960
16
Total ..........................................................
............................
............................
............................
............................
1,082
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
21 CFR Section
No. of recordkeepers
No. of records
per recordkeeper
Total annual
records
Average burden
per recordkeeping
Total hours
810.15(b) ..........................................................
2
1
1
8
8
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
mstockstill on DSK4VPTVN1PROD with NOTICES
Explanation for Burden Estimates
The burden estimates for tables 1 and
2 of this document are based on FDA’s
experience with voluntary recalls under
part 810 of the regulations. FDA expects
no more than two mandatory recalls per
year, as most recalls are done
voluntarily. Since the last time this
collection of information was submitted
to OMB for renewal/approval, there has
been one mandatory recall.
Dated: November 9, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–29512 Filed 11–15–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0377]
Scott S. Reuben: Debarment Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
SUMMARY:
VerDate Mar<15>2010
17:45 Nov 15, 2011
Jkt 226001
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
E:\FR\FM\16NON1.SGM
16NON1
Agencies
[Federal Register Volume 76, Number 221 (Wednesday, November 16, 2011)]
[Notices]
[Pages 71041-71042]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-29512]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0793]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Medical Device Recall Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the information collection
requirements for medical device recall authority.
DATES: Submit either electronic or written comments on the collection
of information by January 17, 2012.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, (301) 796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance
[[Page 71042]]
of FDA's functions, including whether the information will have
practical utility; (2) the accuracy of FDA's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Medical Device Recall Authority--21 CFR Part 810 (OMB Control Number
0910-0432)--Extension
This collection of information implements section 518(e) of the
Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360h(e)) and
part 810 (21 CFR part 810), medical device recall authority provisions.
Section 518(e) of the FD&C Act provides FDA with the authority to issue
an order requiring an appropriate person, including manufacturers,
importers, distributors, and retailers of a device, if FDA finds that
there is reasonable probability that the device intended for human use
would cause serious adverse health consequences or death, to: (1)
Immediately cease distribution of such device, (2) immediately notify
health professionals and device-user facilities of the order, and (3)
instruct such professionals and facilities to cease use of such device.
Further, the provisions under section 518(e) of the FD&C Act set
out the following three-step procedure for issuance of a mandatory
device recall order:
1. If there is a reasonable probability that a device intended for
human use would cause serious, adverse health consequences or death,
FDA may issue a cease distribution and notification order requiring the
appropriate person to immediately:
Cease distribution of the device,
Notify health professionals and device user facilities of
the order, and
Instruct those professionals and facilities to cease use
of the device;
2. FDA will provide the person named in the cease distribution and
notification order with the opportunity for an informal hearing on
whether the order should be modified, vacated, or amended to require a
mandatory recall of the device; and
3. After providing the opportunity for an informal hearing, FDA may
issue a mandatory recall order if the Agency determines that such an
order is necessary.
The information collected under the recall authority provisions
will be used by FDA to do the following: (1) Ensure that all devices
entering the market are safe and effective, (2) accurately and
immediately detect serious problems with medical devices, and (3)
remove dangerous and defective devices from the market.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of No. of responses Total annual Average burden
21 CFR Section respondents per respondent responses per response Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
810.10(d)..................................................... 2 1 2 8 16
810.11(a)..................................................... 1 1 1 8 8
810.12(a) and (b)............................................. 1 1 1 8 8
810.14........................................................ 2 1 2 16 32
810.15(a), (b), and (c)....................................... 2 1 2 12 24
810.15(d)..................................................... 2 1 2 4 8
810.15(e)..................................................... 10 1 10 1 10
810.16(a) and (b)............................................. 2 12 24 40 960
810.17(a)..................................................... 2 1 2 8 16
-----------------------------------------------------------------------------------------
Total..................................................... ................ ................ ................ ................ 1,082
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of No. of records Total annual Average burden
21 CFR Section recordkeepers per recordkeeper records per recordkeeping Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
810.15(b)................................................ 2 1 1 8 8
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Explanation for Burden Estimates
The burden estimates for tables 1 and 2 of this document are based
on FDA's experience with voluntary recalls under part 810 of the
regulations. FDA expects no more than two mandatory recalls per year,
as most recalls are done voluntarily. Since the last time this
collection of information was submitted to OMB for renewal/approval,
there has been one mandatory recall.
Dated: November 9, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-29512 Filed 11-15-11; 8:45 am]
BILLING CODE 4160-01-P